GSK launches single inhaler-triple therapy Trelegy Ellipta to treat COPD in India
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers.
Mumbai: GlaxoSmithKline Pharmaceuticals Limited has recently launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime.
The launch follows the product's approval by the Drugs Controller General of India (DCGI) for use of Trelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) in patients aged 18 and above.
Dr. Rashmi Hegde, Executive Vice President - Medical Affairs, GlaxoSmithKline Pharmaceuticals Limited, said, "We are thrilled to launch Trelegy Ellipta, enabling a greater number of Indian COPD patients to benefit from this world-leading medicine. This is a significant milestone which exemplifies the GSK ambition for patients. Healthcare professionals in India now have a new once-daily, single inhaler triple therapy for the optimal treatment of their COPD patients."
Dr. Deepak Talwar, Director & Chair - Pulmonary, Sleep, Allergy & Critical Care Medicine at Metro Group of Hospitals, said, "COPD is associated with major healthcare and socioeconomic burden on patients and their caregivers. In appropriate patients, studies show that a combination of three different types of medicines for COPD can effectively improve patients' symptoms and reduce the risk of symptom worsening. Considering 75% COPD patients have four or more co-existing medical conditions, the burden of managing and taking many medications may overwhelm patients, resulting in suboptimal treatment. Single-inhaler triple therapy has the potential role to simplify treatment, improve treatment adherence and patient outcomes."
In usual clinical care, treatment with single-inhaler Trelegy Ellipta results in significantly more patients with health status improvements and greater lung benefit, versus multi-inhaler triple therapy, with similar safety profiles. Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers.
Read also: Glenmark gets CDSCO panel nod for Phase 4 study of anti-diabetic FDC drug
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.